{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:58Z","timestamp":1791928858449,"version":"4.3.4"},"reference-count":63,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2\u20133 conventional, dedifferentiated, and mesenchymal CS. The diagnosis of CS combines radiological and histological data in conjunction with patient clinical presentations. Conventional CS is the most frequent subtype of CS (85%) and represents about 25% of primary bone tumors in adults; they can be categorized according to their bone location into central, peripheral, and periosteal chondrosarcomas. Central and peripheral CS differ at the molecular level with either IDH1\/2 mutations or EXT1\/2 mutations, respectively. CDKN2A\/B deletions are also frequent in conventional CS, as well as COL2A1 mutations. Dedifferentiated CS develops when low-grade conventional CS transforms into a high-grade sarcoma and most frequently exhibits features of osteosarcoma, fibrosarcoma, or undifferentiated pleomorphic sarcoma. Their molecular characteristics are similar to conventional CS. Mesenchymal CS is a totally different pathological entity exhibiting recurrent translocations. Their clinical presentation and management are different too. The standard treatment of CSs is wide en-bloc resection. CS are relatively radiotherapy resistant; therefore, doses &gt;60 Gy are needed in an attempt to achieve local control in unresectable tumors. Chemotherapy is possibly effective in mesenchymal chondrosarcoma and is of uncertain value in dedifferentiated chondrosarcoma. Due to resistance to standard anticancer agents, the prognosis is poor in patients with metastatic or unresectable chondrosarcomas. Recently, the refined characterization of the molecular profile, as well as the development of new treatments, allow new therapeutic options for these rare tumors. The efficiency of IDH1 inhibitors in other malignancies suggests that these inhibitors will be part of IDH1\/2 mutated conventional CS management soon. Other treatment approaches, such as PIK3-AKT-mTOR inhibitors, cell cycle inhibitors, and epigenetic or immune modulators based on improving our understanding of CS molecular biology, are emerging.<\/jats:p>","DOI":"10.3390\/ijms24021361","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T02:06:03Z","timestamp":1673402763000},"page":"1361","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-1704","authenticated-orcid":false,"given":"Camille","family":"Tlemsani","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"},{"name":"INSERM U1016-CNRS UMR8104, Cochin Institute, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Larousserie","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-0205","authenticated-orcid":false,"given":"Sixtine","family":"De Percin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Audard","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djihad","family":"Hadjadj","sequence":"additional","affiliation":[{"name":"INSERM U1016-CNRS UMR8104, Cochin Institute, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Biau","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Anract","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Terris","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-8762","authenticated-orcid":false,"given":"Eric","family":"Pasmant","sequence":"additional","affiliation":[{"name":"INSERM U1016-CNRS UMR8104, Cochin Institute, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"},{"name":"Department of Genetics, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-305X","authenticated-orcid":false,"given":"Pascaline","family":"Boudou-Rouquette","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cochin Hospital, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"},{"name":"INSERM U1016-CNRS UMR8104, Cochin Institute, Paris Cancer Institute CARPEM, Universit\u00e9 Paris Cit\u00e9, APHP.Centre, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"De Pinieux, G., Karanian, M., Le Loarer, F., Le Guellec, S., Chabaud, S., Terrier, P., Bouvier, C., Batistella, M., Neuville, A., and Robin, Y.M. (2021). Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246958"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s002560050273","article-title":"Chondrosarcoma as a complicating factor in Paget\u2019s disease of bone","volume":"26","author":"Brandolini","year":"1997","journal-title":"Skelet. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/1055-9965.EPI-12-0810","article-title":"Patterns of bone sarcomas as a second malignancy in relation to radiotherapy in adulthood and histologic type","volume":"21","author":"Wu","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4149\/neo_2014_046","article-title":"Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up","volume":"61","author":"Herget","year":"2014","journal-title":"Neoplasma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"ref_6","unstructured":"Arjen, H.G., and Cleven, J.L.B.R.T. (2020). Periosteal Chondrosarcoma, \u00a9 International Agency for Research on Cancer. WHO Classification of Tumours."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/onc.2011.311","article-title":"Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT","volume":"31","author":"Reijnders","year":"2012","journal-title":"Oncogene"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/his.12666","article-title":"Periosteal chondrosarcoma: A histopathological and molecular analysis of a rare chondrosarcoma subtype","volume":"67","author":"Cleven","year":"2015","journal-title":"Histopathology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00428-014-1685-4","article-title":"Isocitrate dehydrogenase 1 mutations (IDH1) and p16\/CDKN2A copy number change in conventional chondrosarcomas","volume":"466","author":"Amary","year":"2015","journal-title":"Virchows Arch."},{"key":"ref_10","unstructured":"WHO Classification of Tumours Editorial Board (2020). World Health Organization Classification of Soft Tissue and Bone Tumours, IARC Press. [5th ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.suronc.2018.05.009","article-title":"Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas","volume":"27","author":"Ho","year":"2018","journal-title":"Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2105::AID-CNCR9>3.0.CO;2-U","article-title":"Primary chondrosarcoma of long bones and limb girdles","volume":"83","author":"Bjornsson","year":"1998","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13569-017-0074-6","article-title":"IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas","volume":"7","author":"Cleven","year":"2017","journal-title":"Clin. Sarcoma Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.7150\/jca.22915","article-title":"IDH1\/2 Mutations Predict Shorter Survival in Chondrosarcoma","volume":"9","author":"Lugowska","year":"2018","journal-title":"J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2016.108","article-title":"Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype","volume":"29","author":"Kostine","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejca.2007.06.016","article-title":"Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group","volume":"43","author":"Grimer","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: Role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-3329-4-11","article-title":"Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013","volume":"4","author":"Bovee","year":"2014","journal-title":"Clin. Sarcoma Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/PAS.0000000000001441","article-title":"NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma","volume":"44","author":"Yoshida","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0165-4608(93)90020-M","article-title":"A mesenchymal chondrosarcoma of a child with the reciprocal translocation (11;22)(q24;q12)","volume":"71","author":"Sainati","year":"1993","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nyquist, K.B., Panagopoulos, I., Thorsen, J., Haugom, L., Gorunova, L., Bjerkehagen, B., Fossa, A., Guriby, M., Nome, T., and Lothe, R.A. (2012). Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049705"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/gcc.20937","article-title":"Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data","volume":"51","author":"Wang","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1302\/0301-620X.82B1.0820055","article-title":"Experience in the treatment of dedifferentiated chondrosarcoma","volume":"82","author":"Mitchell","year":"2000","journal-title":"J. Bone Joint Surg. Br."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.2106\/00004623-200411000-00008","article-title":"Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes","volume":"86","author":"Dickey","year":"2004","journal-title":"J. Bone Joint Surg. Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/cncr.28845","article-title":"Outcome of advanced, unresectable conventional central chondrosarcoma","volume":"120","author":"Gelderblom","year":"2014","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jso.23617","article-title":"Long-term results of Phase II study of high dose photon\/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas","volume":"110","author":"DeLaney","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Morioka, H., Takahashi, S., Araki, N., Sugiura, H., Ueda, T., Takahashi, M., Yonemoto, T., Hiraga, H., Hiruma, T., and Kunisada, T. (2016). Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2511-y"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nacev, B.A., Smith, S.A., Antonescu, C.R., Rosenbaum, E., Shi, H., Tang, C., Socci, N.D., Rana, S., Gularte-M\u00e9rida, R., and Zehir, A. (2022). Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. medRxiv.","DOI":"10.1038\/s41467-022-30453-x"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00003086-200204000-00011","article-title":"Pathologic neovascularization in cartilage tumors","volume":"397","author":"McGough","year":"2002","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0046-8177(00)80248-8","article-title":"Microvasculature and VEGF expression in cartilaginous tumors","volume":"31","author":"Ayala","year":"2000","journal-title":"Hum. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cncr.25632","article-title":"A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: An Italian Sarcoma Group study","volume":"117","author":"Grignani","year":"2011","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1002\/cam4.4286","article-title":"Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study","volume":"10","author":"Liu","year":"2021","journal-title":"Cancer Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.03.039","article-title":"Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study","volume":"150","author":"Duffaud","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(13)70049-4","article-title":"Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial","volume":"14","author":"Schwartz","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PAP.0b013e31827b654d","article-title":"Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors","volume":"20","author":"Schaap","year":"2013","journal-title":"Adv. Anat. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1724600818774464","article-title":"Expression of PD-L1\/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma","volume":"33","author":"Yang","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.jbo.2019.100271","article-title":"The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target","volume":"20","author":"Iseulys","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1634\/theoncologist.2017-0290","article-title":"Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience","volume":"23","author":"Cote","year":"2018","journal-title":"Oncologist"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of Doxorubicin and Pembrolizumab in Patients with Advanced Anthracycline-Naive Sarcoma: A Phase 1\/2 Nonrandomized Clinical Trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00068","article-title":"Palbociclib in Patients with Pancreatic and Biliary Cancer with CDKN2A Alterations: Results from the Targeted Agent and Profiling Utilization Registry Study","volume":"3","author":"Halabi","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Conciatori, F., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., Milella, M., and Ciuffreda, L. (2018). Role of mTOR Signaling in Tumor Microenvironment: An Overview. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082453"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","article-title":"Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-012-1968-x","article-title":"Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas","volume":"70","author":"Kollender","year":"2012","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ijc.28083","article-title":"A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma","volume":"133","author":"Thornton","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.tcb.2017.06.002","article-title":"Oncogenic Activities of IDH1\/2 Mutations: From Epigenetics to Cellular Signaling","volume":"27","author":"Boulay","year":"2017","journal-title":"Trends Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Venneker, S., Kruisselbrink, A.B., Baranski, Z., Palubeckaite, I., Briaire-de Bruijn, I.H., Oosting, J., French, P.J., Danen, E.H.J., and Bovee, J. (2020). Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 12.","DOI":"10.3390\/cancers12123589"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrc3876","article-title":"The emerging roles of YAP and TAZ in cancer","volume":"15","author":"Moroishi","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","article-title":"Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine","volume":"20","author":"Moya","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.redar.2019.05.003","article-title":"Median nerve block in the forearm and persistent median artery","volume":"66","author":"Fervienza","year":"2019","journal-title":"Rev. Esp. Anestesiol. Reanim."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1110955","article-title":"TAZ, a transcriptional modulator of mesenchymal stem cell differentiation","volume":"309","author":"Hong","year":"2005","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.celrep.2016.02.021","article-title":"Yap1 Regulates Multiple Steps of Chondrocyte Differentiation during Skeletal Development and Bone Repair","volume":"14","author":"Deng","year":"2016","journal-title":"Cell Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"30094","DOI":"10.18632\/oncotarget.8979","article-title":"TAZ and YAP are frequently activated oncoproteins in sarcomas","volume":"7","author":"Fullenkamp","year":"2016","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/jcb.25863","article-title":"The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP\/p21\/c-Myc Signaling","volume":"118","author":"Zhang","year":"2017","journal-title":"J. Cell Biochem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2353\/ajpath.2006.050001","article-title":"Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation","volume":"168","author":"Tiet","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1535-7163.MCT-13-0731","article-title":"Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth","volume":"13","author":"Campbell","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/annonc\/mdt391","article-title":"GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group\/US and French National Cancer Institute Single-Arm Phase II Collaborative Study","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1361\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:48Z","timestamp":1760119548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021361"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021361","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}